INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $89,245 | -8.5% | 1,753 | +13.8% | 0.00% | -20.0% |
| Q2 2023 | $97,513 | +0.1% | 1,540 | 0.0% | 0.01% | 0.0% |
| Q1 2023 | $97,405 | +4501.1% | 1,540 | +3750.0% | 0.01% | – |
| Q4 2022 | $2,117 | +5.8% | 40 | 0.0% | 0.00% | – |
| Q3 2022 | $2,000 | 0.0% | 40 | 0.0% | 0.00% | – |
| Q2 2022 | $2,000 | 0.0% | 40 | 0.0% | 0.00% | – |
| Q1 2022 | $2,000 | -93.8% | 40 | -95.4% | 0.00% | -100.0% |
| Q3 2021 | $32,000 | -8.6% | 863 | 0.0% | 0.00% | -25.0% |
| Q2 2021 | $35,000 | +12.9% | 863 | -4.5% | 0.00% | 0.0% |
| Q1 2021 | $31,000 | +10.7% | 904 | +1.3% | 0.00% | 0.0% |
| Q4 2020 | $28,000 | +27.3% | 892 | +4.3% | 0.00% | +33.3% |
| Q3 2020 | $22,000 | +15.8% | 855 | +15.2% | 0.00% | 0.0% |
| Q2 2020 | $19,000 | +171.4% | 742 | +61.7% | 0.00% | +200.0% |
| Q1 2020 | $7,000 | -58.8% | 459 | -9.6% | 0.00% | -66.7% |
| Q4 2019 | $17,000 | +142.9% | 508 | -45.7% | 0.00% | +200.0% |
| Q3 2019 | $7,000 | – | 935 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |